Tango Therapeutics Inc (TNGX)
7.55
-0.24
(-3.08%)
USD |
NASDAQ |
May 17, 16:00
7.55
0.00 (0.00%)
After-Hours: 20:00
Tango Therapeutics Research and Development Expense (Quarterly): 38.06M for March 31, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 38.06M |
| December 31, 2023 | 31.34M |
| September 30, 2023 | 27.15M |
| June 30, 2023 | 28.67M |
| March 31, 2023 | 28.04M |
| December 31, 2022 | 29.09M |
| September 30, 2022 | 28.74M |
| June 30, 2022 | 23.74M |
| Date | Value |
|---|---|
| March 31, 2022 | 24.33M |
| December 31, 2021 | 21.63M |
| September 30, 2021 | 21.92M |
| June 30, 2021 | 19.08M |
| March 31, 2021 | 15.00M |
| December 31, 2020 | 15.06M |
| September 30, 2020 | 12.98M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
12.98M
Minimum
Sep 2020
38.06M
Maximum
Mar 2024
24.32M
Average
24.33M
Median
Mar 2022
Research and Development Expense (Quarterly) Benchmarks
| Aquestive Therapeutics Inc | 5.932M |
| 2seventy bio Inc | 43.93M |
| NovaBay Pharmaceuticals Inc | 0.019M |
| Palatin Technologies Inc | 7.160M |
| iBio Inc | 1.535M |